May 8, 2012

For immediate release:

Japanese Red Cross Society
Mitsubishi Tanabe Pharma Corporation

New Organization in Plasma Fractionation Operations
Establishment of “Japan Blood Products Organization”

The Japanese Red Cross Society (National Headquarters: Minato-ku, Tokyo; President: Tadateru Konoe) and Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; President and Representative Director: Michihiro Tsuchiya), in accordance with a basic agreement reached on June 17, 2011, have carefully considered the integration of the plasma fractionation operations of the Japanese Red Cross Society and Benesis Corporation, a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation that is engaged in the production and sale of plasma fractionation products.

The two parties have agreed to establish the “Japan Blood Products Organization” and to transfer their plasma fractionation operations to the new organization, with operations scheduled to commence on October 1, 2012.

With priority on the public welfare, the Japan Blood Products Organization will work to achieve the goal of national self-sufficiency by blood products made from plasma obtained through voluntary non-remunerated blood donation. The organization will secure sound operations by leveraging economies of scale to reduce costs at the production and supply stages.

The Japanese Red Cross Society and Mitsubishi Tanabe Pharma Corporation believe that the Japan Blood Products Organization will make a broad contribution to enhancing the health of people in Japan in the years ahead by contributing to the achievement of national self-sufficiency in plasma fractionation products in accordance with the basic principles of the Act on Securing a Stable Supply of Safe Blood Products.
An overview of the new organization is shown on the next page.

End.

For further information:

Japanese Red Cross Society,
Blood Service Headquarters, Management Planning
TEL: +81-3-3437-7708

Mitsubishi Tanabe Pharma Corporation,
Corporate Communications Department
TEL: +81-6-6205-5211
Overview of the new Organization

Name: Japan Blood Products Organization

Head office: World Trade Center Building, 7th Floor, 2-4-1 Hamamatsu-cho, Minato-ku, Tokyo

Production facilities: 1007-31 Izumisawa, Chitose City, Hokkaido 2-11 Osadano-cho, Fukuchiyama City, Kyoto

R&D facilities: Kobe City, Hyogo (planned)

Start of operations: October 1, 2012 (planned)

Representative: President, Hidehiko Ueda  
(currently, Executive Officer, Blood Service Board of Management, Japanese Red Cross Society.)  
Vice President, Yuji Akiyama  
(currently, Advisor, Benesis Corporation)

No. of employees: About 900

Sales: About ¥37.0 billion on an NHI price basis  
(sum of the sales of the plasma fractionation products of the two parties)

Principal products:  
(1) Human Immunoglobulin  
• Nisseeki Polyclavin® N 5% I.V. 5g/100mL  
 (currently Japanese Red Cross Society product)  
• Venoglobulin® IH 5% I.V. 5g/100mL  
 (currently Benesis product)  
(2) Human Serum Albumin  
• Sekijuji Albumin 25% I.V. 12.5g/50mL  
 (currently Japanese Red Cross Society product)  
• Albumin 25% I.V. 12.5g/50mL-BENESIS  
 (currently Benesis product)
- Sekijuji Albumin 20% I.V. 10g/50mL (currently Japanese Red Cross Society product)
- Albumin 5% I.V. 12.5g/250mL BENESIS (currently Benesis product)
- Sekijuji Albumin 5% I.V. 12.5g/250mL (currently Japanese Red Cross Society product)

(3) Coagulation Factor VIII
- CROSS EIGHT M® for I.V. 1000 units (currently Japanese Red Cross Society product)

(4) Human Anti-HBs Immunoglobulin
- Anti-HBs Human Immune Globulin I.M. 200 units/1 mL, “Nissee” (currently Japanese Red Cross Society product)
- Hebsbulin® IH I.V. 1000 units (currently Benesis product)

(5) Lyophilized Human Antithrombin III
- Neuart® I.V. 1500 units (currently Benesis product)

(6) Human Haptoglobin
- Haptoglobin I.V. 2000 units BENESIS (currently Benesis product)

(Reference) New logo